AEACaP and Lung Cancer Europe (LuCE) host “ROS-1 Lung Cancer Patients” webinar on 26-Mar-2021


The Spanish Association of Lung Cancer Patients (AEACaP) and Lung Cancer Europe (LuCE) will be hosting the webinar “ROS-1 Lung Cancer Patients” on Friday, March 26th, 2021 at 18.00 Central European Time (10 am Pacific Time). The event will provide information about the ROS1 biomarker and treatment in lung cancer, as well as research and … Continue reading AEACaP and Lung Cancer Europe (LuCE) host “ROS-1 Lung Cancer Patients” webinar on 26-Mar-2021

The ROS1ders publishes report to move ROS1+ cancer research forward


Today The ROS1ders published a white paper titled, “Sustaining and Accelerating Research for ROS1 Cancer.” The document summarizes key themes and subsequent discussions from two ROS1ders Research Roundtable virtual meetings, which brought together members of The ROS1ders with leading ROS1 clinicians and researchers. The report also offers a “Call to Action” to help move ROS1 … Continue reading The ROS1ders publishes report to move ROS1+ cancer research forward

Last Chance to register for @IASLC #TTLC21


LAST CHANCE to register for the IASLC 2020 Targeted Therapies in Lung Cancer Meeting (to be held THIS WEEK February 17-20). The program is a series of 5-minute presentations on lab research and clinical trials for targeted therapies. The session on ALK & ROS1 inhibitors happens on Thursday February 18 at 14:40 Eastern Time.   This … Continue reading Last Chance to register for @IASLC #TTLC21

Pulmonary hypertension in ROS1+ patients on TKIs


Two independent studies found ROS1+ lung cancer patients are more likely to develop blood clots than patients who have other lung cancers. Pulmonary embolisms are not uncommon in the ROS1ders, and these types of blood clots can eventually result in pulmonary hypertension (because it increases pressure on the heart). The appearance of a new blood … Continue reading Pulmonary hypertension in ROS1+ patients on TKIs

ROS1derings Winter 2020 (The ROS1ders newsletter)


Welcome to the Winter 2020 issue of ROS1derings, the newsletter of The ROS1ders! This issue contains info about on our patient-driven research, a fundraising update, a summary of current targeted therapies for ROS1+ cancers, and tips on parenting after a ROS1+ cancer diagnosis. Thanks to editors Joyce Hoelting and Jeff Wynne, and contributors Lisa Goldman, … Continue reading ROS1derings Winter 2020 (The ROS1ders newsletter)

Thanks to ROS1ders’ Partner Turning Point Therapeutics


Dear Turning Point Therapeutics, Thank you so much for inviting me to speak to your employees about my personal ROS1 lung cancer story and the work of The ROS1ders. I truly appreciate your willingness to consider a patient perspective on ways to improve awareness of and access to biomarker testing and clinical trials for cancer patients. … Continue reading Thanks to ROS1ders’ Partner Turning Point Therapeutics